Macrogenics Inc
MGNX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001125345
In the last 90 days, Macrogenics Inc insiders filed 0 open-market purchases and 1 sale; 122 institutions reported holding it in 13F filings for Q2 2026, worth $224.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Macrogenics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $129.1K in total
- Insiders trading
- 1
- Net value
- −$129.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Macrogenics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Peters Jeffrey Stuart | Senior VP, GC, and Secretary | 0 | Aug 20, 2026 | 3 |
| Bonvini Ezio | Sr VP, Research & CSO | 185,799 | Aug 18, 2026 | 3 |
| O'Brien Federica F. | Director | 14,750 | May 20, 2026 | 1 |
| Stump David C | Director | 14,750 | May 20, 2026 | 1 |
| Hurwitz Edward | Director | 47,824 | May 20, 2026 | 1 |
| Heiden William K | Director | 114,750 | May 20, 2026 | 1 |
| Liu Margaret | Director | 14,750 | May 20, 2026 | 1 |
| Chhabra Meenu | Director | 14,750 | May 20, 2026 | 1 |
| Jackson Scott Thomas | Director | 14,750 | May 20, 2026 | 1 |
| Koenig Scott | Director | 867,240 | May 20, 2026 | 3 |
| Ferrante Karen Jean | Director | 14,750 | May 20, 2026 | 1 |
| Siegel Jay Philip | Director | 14,750 | May 20, 2026 | 1 |
| Karrels James | SVP and CFO | 206,037 | Feb 17, 2026 | 2 |
| Risser Eric Blasius | President and CEO | 77,169 | Feb 17, 2026 | 2 |
| Spitznagel Thomas | Sr VP, Technical Ops | 38,543 | Feb 17, 2026 | 2 |
| Smith Beth Ann | VP, Controller & Treasurer | 12,781 | Feb 17, 2026 | 3 |
| Eck Stephen L. | Chief Medical Officer | 29,377 | Feb 19, 2025 | 0 |
| Cilinski Lynn | VP, Controller and Treasurer | 6,213 | Feb 20, 2024 | 0 |
| BB Biotech AG | 10% Owner | 9,929,963 | Oct 4, 2023 | 0 |
| Biotech Target N V | 10% Owner | 9,929,963 | Oct 4, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)6:19 PM ET | Aug 19 | 1 day | Peters Jeffrey StuartSenior VP, GC, and Secretary | SSale | −31.1K | $4.15 | −$129.1K | −100.0%0 after | 10b5-1 |
| Aug 21, 2025 (view filing) | Aug 19-20 | 2 days | Heiden William KDirector | PPurchase | +100.0K | $1.51 | +$150.5K | +909.1%111.0K after | 2 lots |
| Feb 19, 2025 (view filing) | Feb 15 | 4 days | Smith Beth AnnVP, Controller & Treasurer | SSale | −423 | $2.56 | −$1.08K | −4.2%9.53K after | |
| Apr 8, 2024 (view filing) | Apr 4 | 4 days | Peters Jeffrey StuartSenior VP and General Counsel | SSale | −51.4K | $15.55 | −$799.1K | −100.0%0 after | 5 lots10b5-1 |
| Mar 8, 2024 (view filing) | Mar 6 | 2 days | Peters Jeffrey StuartSenior VP and General Counsel | SSale | −19.6K | $21.50 | −$421.9K | −68.8%8.89K after | 10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Risser Eric BlasiusChief Operating Officer | SSale | −41.2K | $19.76 | −$813.5K | −51.4%38.9K after | 2 lots10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Spitznagel ThomasSr VP, Technical Ops | SSale | −10.0K | $20.00 | −$200.0K | −54.6%8.32K after | 10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Karrels JamesSVP, CFO and Secretary | SSale | −30.0K | $20.50 | −$615.0K | −14.9%171.5K after | 10b5-1 |
| Feb 28, 2024 (view filing) | Feb 26 | 2 days | Peters Jeffrey StuartSenior VP and General Counsel | SSale | −16.1K | $17.22 | −$277.7K | −64.4%8.89K after | 10b5-1 |
| Feb 7, 2024 (view filing) | Feb 7 | Same day | Bonvini EzioSr VP, Research & CSO | SSale | −3.33K | $18.00 | −$60.0K | −4.5%71.3K after | 10b5-1 |
| Feb 7, 2024 (view filing) | Feb 5 | 2 days | Peters Jeffrey StuartSenior VP and General Counsel | SSale | −76.3K | $16.50 | −$1.26M | −100.0%0 after | 2 lots10b5-1 |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Bonvini EzioSr VP, Research & CSO | SSale | −13.3K | $15.00 | −$199.7K | −15.1%74.7K after | 10b5-1 |
| Jan 22, 2024 (view filing) | Jan 19 | 3 days | Bonvini EzioSr VP, Research & CSO | SSale | −13.3K | $12.00 | −$159.8K | −13.1%88.0K after | 10b5-1 |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | Bonvini EzioSr VP, Research & CSO | SSale | −18.9K | $10.08 | −$190.3K | −15.7%101.3K after | 10b5-1 |
| Oct 4, 2023 (view filing)3:31 PM ET | Oct 2 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +150.0K | $4.46 | +$669.6K | +1.5%9.93M after | |
| Sep 11, 2023 (view filing)3:39 PM ET | Sep 7 | 4 days | BB Biotech AG and 1 other10% Owner | PPurchase | +200.0K | $5.26 | +$1.05M | +2.1%9.78M after | |
| Sep 1, 2023 (view filing) | Aug 30 | 2 days | Hurwitz EdwardDirector | PPurchase | +15.0K | $4.91 | +$73.7K | +83.0%33.1K after | |
| Mar 14, 2023 (view filing) | Mar 10 | 4 days | Peters Jeffrey StuartSenior VP and General Counsel | SSale | −5.37K | $6.03 | −$32.4K | −100.0%0 after | |
| Feb 16, 2023 (view filing)12:37 PM ET | Feb 14 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +500.0K | $5.07 | +$2.53M | +5.5%9.58M after | |
| Jan 23, 2023 (view filing)4:21 PM ET | Jan 19 | 4 days | BB Biotech AG and 1 other10% Owner | PPurchase | +150.0K | $5.30 | +$794.9K | +1.7%9.08M after | |
| Dec 28, 2022 (view filing)11:03 AM ET | Dec 23-27 | 5 days | BB Biotech AG and 1 other10% Owner | PPurchase | +400.0K | $5.75 | +$2.30M | +4.7%8.93M after | 2 lots |
| Nov 25, 2022 (view filing)11:37 AM ET | Nov 22 | 3 days | BB Biotech AG and 1 other10% Owner | PPurchase | +300.0K | $5.96 | +$1.79M | +3.6%8.53M after | |
| Oct 25, 2022 (view filing)4:19 PM ET | Oct 21-24 | 4 days | BB Biotech AG and 1 other10% Owner | PPurchase | +500.0K | $4.50 | +$2.25M | +6.5%8.23M after | 2 lots |
| Oct 21, 2022 (view filing)3:03 PM ET | Oct 19-20 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +454.4K | $3.89 | +$1.77M | +6.2%7.73M after | 2 lots |
| Jun 17, 2022 (view filing) | Jun 15 | 2 days | Karrels JamesSVP, CFO and Secretary | PPurchase | +40.0K | $2.47 | +$98.8K | +26.4%191.8K after | |
| Nov 23, 2021 (view filing)12:29 PM ET | Nov 19 | 4 days | BB Biotech AG and 1 other10% Owner | PPurchase | +200.0K | $18.50 | +$3.70M | +2.8%7.28M after | |
| Sep 30, 2021 (view filing)3:09 PM ET | Sep 28-29 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +200.0K | $20.56 | +$4.11M | +2.9%7.08M after | 2 lots |
| Sep 20, 2021 (view filing)12:21 PM ET | Sep 16-17 | 4 days | BB Biotech AG and 1 other10% Owner | PPurchase | +600.0K | $20.61 | +$12.4M | +9.6%6.88M after | 2 lots |
| Jul 20, 2021 (view filing) | Jul 16 | 4 days | Spitznagel ThomasSr VP, BPD & Manufacturing | SSale | −5.00K | $25.01 | −$125.0K | −100.0%0 after |